Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the physical impact of Multiple Sclerosis MS from the patients perspective while providing continued access to the drug ocrelizumab. This extension study evaluates the safety and tolerability of ocrelizumab in patients previously enrolled in certain parent studies who no longer have local access to the treatment. The study is open-label and multicenter, sponsored by Hoffmann-La Roche. Participants will receive ocrelizumab at approved doses of either 600 mg via intravenous infusion or 920 mg via subcutaneous injection, following the schedule from their original parent study. Treatment will continue until the medication becomes locally available, an unacceptable safety concern arises, the participant dies, or withdraws consent. During the study, participants will be monitored for changes in physical function using patient-reported outcome measures over up to five years. Researchers will also track access to ocrelizumab, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. The study will last up to five years, with ongoing safety and tolerability assessments throughout the treatment period.
Actively Recruiting
Researchers are evaluating the safety, efficacy, and tolerability of sodium zirconium cyclosilicate SZC in children under 18 years old with hyperkalaemia, a condition involving high potassium levels. This phase 3, open-label study involves about 140 participants across roughly 46 sites in Europe, North America, and other locations. It starts with two age cohorts 6 to under 12 years and 12 to under 18 years, with potential expansion to younger cohorts based on data review by an independent monitoring committee. Treatment includes three phases the Correction Phase CP, Maintenance Phase MP, and Long-Term Maintenance Phase LTMP. Participants in CP receive SZC orally three times daily for up to 3 days until potassium levels normalize, with doses adjusted by body weight equivalent to adult doses of 5 g, 10 g, or 15 g. Those achieving normal potassium enter the MP, receiving once-daily SZC for 28 days with dose adjustments to maintain levels. Participants may then continue into the LTMP, following a similar dose regimen with monthly visits. Throughout the study, participants undergo blood tests, ECG monitoring, urine analyses, and safety assessments to track potassium levels, aldosterone, electrolytes, and kidney function. Researchers measure effectiveness by the ability to achieve and maintain normal potassium levels and monitor safety and tolerability in all phases. The study duration is about 28 weeks, including treatment and a safety follow-up one week after the last dose.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a cervical cancer screening program using self-sampling for human papillomavirus HPV detection among women aged 30 to 60 years in the Zaporizhzhia region of Ukraine. This area has faced disruption due to armed conflict, which has affected traditional access to preventive services. The study aims to improve screening access, assess the feasibility of self-sampling in conflict conditions, and support the development of a sustainable cervical cancer control model applicable to similar challenging settings. The project is a collaboration between local Ukrainian institutions and Karolinska Institutet in Sweden, supported by an international cancer control organization. Participants receive an HPV self-sampling kit distributed through primary care providers, community outreach, or partner organizations. Women collect a vaginal sample themselves using the provided FLOQSwab device and return it to clinics or volunteers free of charge. Samples undergo testing for high-risk HPV types in accredited molecular laboratories with quality assurance processes. HPV-positive women receive follow-up care according to national guidelines, including referral for further examination and treatment if needed. HPV-negative women are reassured and advised on future screening intervals. The study also includes training for healthcare providers and uses a secure digital platform to manage registrations, results, and follow-up coordination. During the study, participants will be evaluated on their acceptance of self-sampling and follow-up procedures. Data will be collected on participation rates, test results, and adherence to follow-up care. Surveys and interviews with both participants and healthcare providers will assess the programs feasibility, acceptability, and sustainability amid ongoing conflict challenges such as migration and disrupted health services. The primary outcome is the uptake of HPV self-sampling within 12 weeks, with additional outcomes measuring provider adoption, test performance, and follow-up completion. The study is expected to last up to 24 months, aiming to reach about 1,000 eligible women.
Actively Recruiting
This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.
Actively Recruiting
Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.
Actively Recruiting
Researchers are evaluating the use of the Abdominal Aortic and Junctional Tourniquet - Stabilized AAJT-S device as a temporary treatment for severe postpartum hemorrhage PPH caused by uterine atony that does not respond to standard therapies like uterotonics and balloon tamponade. This multicenter, prospective study focuses on women experiencing heavy bleeding after childbirth in settings where surgical care and blood products may be delayed, such as conflict-affected regions in Ukraine. Participants will receive standard care for PPH initially. If bleeding continues uncontrolled, the AAJT-S device will be applied to the upper abdomen and inflated to 250 mmHg to temporarily block blood flow through the abdominal aorta and inferior vena cava. This device will be used for up to 60 minutes to reduce bleeding and provide time to prepare for surgery and blood transfusion. During the study, women will be closely monitored from device application until six weeks postpartum. Researchers will measure how quickly bleeding is controlled after device use and watch for any device-related side effects. Blood loss will also be estimated visually from delivery until the device is placed. This monitoring aims to assess the devices feasibility, safety, and effectiveness as a temporary intervention for severe PPH.